Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
Non-small Cell Lung Cancer
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic…
- Trial name
- KEYNOTE-799 (NCT03631784)
- Testing
- Pembrolizumab 200 mg, Paclitaxel 45 mg/m^2, Carboplatin AUC6
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC
First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy
This is a non-interventional/observational cohort of unresectable Stage III NSCLC patients treated with durvalumab. The study will be carried out as a retrospective review of established medical records of unresectable Stage III…
- Trial name
- NCT03798535
- Where
- 254 sites in Australia, Belgium and 8 more
- Volunteers
- 1,156 people
- Sponsor
- AstraZeneca
Lung Cancer
SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00002642
- Testing
- cisplatin, etoposide, conventional surgery
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer, NSCLC
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
The use of induction chemotherapy is feasible and effective. It is also logistically beneficial for decreasing micrometastases and radiation-related toxicity by decreasing tumor burden before definite locoregional concurrent…
- Trial name
- NCT00620269
- Testing
- Erlotinib, Induction or consolidation IP chemotherapy, CCRT with IP chemotherapy (Irinotecan + Cisplatin)
- Where
- South Korea
- Volunteers
- 212 people
- Sponsor
- National Cancer Center, Korea
Non-small Cell Lung Cancer
A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer
This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.
- Trial name
- NCT04958993
- Testing
- Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Shandong Cancer Hospital and Institute
Stage III Non-small Cell Lung Cancer
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG…
- Trial name
- NVALT31-PET (NCT06082492)
- Testing
- 18F FDG PET/CT, CT scan
- Where
- 27 sites in Netherlands
- Volunteers
- 690 people
- Sponsor
- Radboud University Medical Center
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma.
- Conditions
- Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma
- Trial name
- NCT02408016
- Testing
- Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-small Cell Lung Cancer
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung…
- Trial name
- START (NCT00409188)
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide
- Where
- 290 sites in United States, Argentina and 31 more
- Volunteers
- 1,513 people
- Sponsor
- EMD Serono
Metastatic NSCLC - Non-Small Cell Lung Cancer
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes.
- Trial name
- NCT07149649
- Testing
- Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose
- Where
- 9 sites in Switzerland
- Volunteers
- 230 people
- Sponsor
- Swiss Cancer Institute
Fatigue, Lung Cancer
Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer
RATIONALE: Radiation therapy may relieve symptoms in patients with non-small cell lung cancer. It is not yet known which regimen of radiation therapy is most effective in relieving symptoms in patients with non-small cell lung…
- Conditions
- Fatigue, Lung Cancer, Nausea and Vomiting, Pain
- Trial name
- NCT00003685
- Testing
- fatigue assessment and management, nausea and vomiting therapy, pain therapy
- Where
- 21 sites in Canada
- Volunteers
- 230 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small Cell Lung Cancer, NSCLC
Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer
The investigators aim to evaluate the safety of delivering a one-time single fraction of Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose, conventionally fractionated concurrent…
- Trial name
- NCT01797471
- Testing
- Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
NSCLC
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral…
- Trial name
- NCT00683514
- Testing
- Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
- Where
- Germany
- Volunteers
- 201 people
- Sponsor
- Pierre Fabre Medicament
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
This phase I/II trial studies the side effects and best dose of vorinostat when given together with paclitaxel and radiation therapy and to see how well it works in treating patients unable to tolerate cisplatin with stage III…
- Trial name
- NCT00662311
- Testing
- vorinostat, paclitaxel, radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Non-small Cell Lung Cancer Stage III
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
Standard treatment for stage III Non-Small Cells Lung Cancer (NSCLC) not eligibile for surgery is concomitant chemoradiotherapy.
- Trial name
- BRIDGE (NCT04765709)
- Testing
- durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed), Durvalumab plus radiotherapy, durvalumab
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Unresectable Stage III NSCLC
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
This is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with locally advanced, unresectable NSCLC (Stage…
- Trial name
- NCT04982549
- Testing
- Durvalumab, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Shandong Cancer Hospital and Institute
Lung Cancer
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00547443
- Testing
- carboplatin, paclitaxel, sorafenib tosylate
- Where
- 2 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Non Small Cell Lung Carcinoma
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or…
- Trial name
- NCT00234468
- Testing
- Iressa (Gefitinib)
- Where
- 32 sites in Italy
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Lung Cancer
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, irinotecan, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449020
- Testing
- Carboplatin, Docetaxel, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Miami
NSCLC (Non-small-cell Lung Cancer)
Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC
This is a single-arm, multicenter Phase II clinical study designed to observe and evaluate the efficacy and safety of Iparomlimab and tuvonralimab plus chemotherapy in initially unresectable Stage III NSCLC.
- Trial name
- NCT07139041
- Testing
- Iparomlimab and tuvonralimab plus chemotherapy
- Volunteers
- 69 people
- Sponsor
- Chang Chen
NSCLC, Stage III
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.
- Trial name
- NCT05611879
- Testing
- Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC), Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital